References
- Stăcescu S, Hancu G, Gagyi L, Soare R, Kelemen H. Simultaneous determination of hydrochlorothiazide and telmisartan from pharmaceutical preparations using capillary electrophoresis. Studia UBB Chemia. 2017; 52(2):189-198.
- Korhonen P, Vesalainen R, Aarnio P, Kautiainen H, Järvenpää S, Kantola I. Assessment of cardiovascular risk in primary health care. Scand J Prim Health Care. 2012; 30:101-106.
- Dorobantu M, Tautu OF, Darabont R, et al. Objectives and methodology of Romanian SEPHAR II Survey. Project for comparing the prevalence and control of cardiovascular risk factors in two East-European countries: Romania and Poland. Arch Med Sci. 2015; 11(4):715-723.
- Massimo FP, Hoes AW, Agewall S, et al. 2016 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2016; 37: 2315–2381.
- Dorobantu M, Bartos D, Apetrei E, et al. Hypertension in Romania: Where are we and what can we do? Results from SEPHAR II study. Rom J Cardiol. 2012; 22(4):285-290.
- Bálint I, Nemes-Nagy E, Csibi M, et al. The role of diet and lifestyle habits in prevention of cardiovascular diseases in Moldavian and Transylvanian population. Rev Chim. 2017; 68:1460-1465.
- Hilary J, Gallagher PF, O’Mahony D. Inappropriate prescribing and adverse drug events in older people. BMC Geriatrics. 2009; 9(1):1-4.
- Hyon KC, Soriano LC, Zhang Y, Rodriguez LAG. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012; 344:81-90.
- Dent A, Walmsley D, Dhandapani S. Hyperkalemia is a risk with low sodium salt in vulnerable patients. BMJ. 2011; 343:4514.
- Amir O, Hassan Y, Sarriff A, Awaisu A, Abd Aziz N, Ismail O. Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases. Pharm World Sci. 2009; 31:387-393.
- Manns B, Hemmelgarn B, Tonelli M, et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ. 2010; 341:c5869.
- Cruz CS, Cruz AA, Marcílio de Souza CA. Hyperkalemia in congestive heart failure patients using ACEI and spironolactone. Nephrol Dial Transplant. 2003; 18:1814-1819.
- Montalescot G, Collet JP. Preserving cardiac function in the hypertensive patient: Why renal parameters hold the key. Eur Heart J. 2005; 26(24):2616-2622.
- Ochodnicky P, Henning RH, Van Dokkum RPE, De Zeeuw D. Microalbuminuria and endothelial dysfunction: Emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol. 2006; 47:S151-S162.
- Donnelly R, Yeung JMC, Manning G. Microalbuminuria: A common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. J Hypertens. 2003; 21(suppl 1): S7-S12.
- Holmes HM, Luo R, Hanlon JT, Elting LS, Suarez-Almazor M, Goodwin JS. Ethnic disparities in adherence to antihypertensive medications of medicare part D beneficiaries. J Am Geriatr Soc. 2012; 60(7):1298-1303.
- Fogarasi E, Croitoru MD, Fülöp I, et al. Malondialdehyde levels can be measured in serum and saliva by using a fast HPLC method with visible detection; Rev Rom Med Lab; 2016; 24(3):319-326.
- Tarcea M, Fazakas Z, Szucs V, et al. Mean Dietary Fiber Intake of Romanian Adults Results of a Survey Questionnaire. Rev Chim. 2017; 68(9):2083-2087.
- Floege J, Johnson RJ, Feehally J. Comprehensive Clinical Nephrology. 4th ed. Philadelphia, PA. Saunders Elsevier. 2010;118-129.
- Guyton AC, Hall JE (eds). Unit V: The Body Fluids and Kidneys in Textbook of Medical Physiology. 11th Edition. Elsevier. Philadelphia, PA. 2005.
- Lieberman M, Marks AD (eds). Mark’s Basic Medical Biochemistry A Clinical Approach. 3rd Ed. Lippincott Williams & Wilkins. Philadelphia, PA. 2009.
- Ray K, Dorman S, Watson R.: Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life-threatening interaction. J Hum Hypertens. 1999; 13:717-20.